Cytokinetics Q3 net loss widens to $306.2 million as revenue rises to $1.9 million
Cytokinetics reported third quarter 2025 results on November 5, 2025, with revenue of $1.9 million, up from $0.5 million a year earlier. The net loss widened to $306.2 million, or $(2.55) per share, from $160.5 million, or $(1.36) per share, including a $121.2 million debt conversion expense tied to the exchange of $399.5 million of 2027 Notes. The company narrowed its full-year 2025 GAAP operating expense guidance to $680 million to $700 million from $670 million to $710 million, and said it is preparing for the December 26, 2025 FDA action date for aficamten.
Key points
- Q3 2025 total revenues were $1.9 million, compared with $0.5 million in Q3 2024.
- Q3 2025 net loss was $306.2 million, or $(2.55) per share, versus $160.5 million, or $(1.36) per share, a year earlier.
- Full-year 2025 GAAP operating expense guidance is $680 million to $700 million, versus a prior range of $670 million to $710 million.
- Cash, cash equivalents and investments were approximately $1.25 billion as of September 30, 2025.
The filing
Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.